Value-Based Cancer Care Issues

September 2014, Vol 5, No 7

Oncologists Can Become Value-Based Providers Using Evidence to Guide Patient Care

Wayne Kuznar

Value in Oncology

Chicago, IL—Oncologists should become value-based providers by eliminating unnecessary tests, prescribing cheaper alternatives when therapeutic equivalents exist, and keep calling for payment reform, said Ezekiel J. Emanuel, MD, PhD, Chair, Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, at the 2014 American Society of Clinical Oncology meeting, during a session on defining value from different stakeholder perspectives. [ Read More ]

Oncologists Must Begin to Address Value in Patient Care

Dana Butler

Value in Oncology

Chicago, IL—The topic of value in cancer care was addressed at a special session at the 2014 American Society of Clinical Oncology (ASCO) meeting. Lowell E. Schnipper, MD, Harvard Medical School, Boston, and Chair of the ASCO Task Force on Value in Cancer Care noted that value is not about the number of dollars spent but rather about the cost of a treatment to a patient, who may experience financial and physical toxicities. [ Read More ]

Bortezomib Receives New FDA Indication for Retreatment of Patients with Myeloma

FDA Approvals, News & Updates

Bortezomib (Velcade; Millennium/Takeda Oncology), which is already approved by the FDA as an intravenous (IV) or subcutaneous treatment for patients with multiple myeloma, recently received a supplemental new indication for the retreatment of adults with myeloma whose disease had previously responded to bortezomib therapy and had relapsed (ie, progressed) at least 6 months after the last treatment with bortezomib. [ Read More ]

In the Literature – September 2014

In the Literature

Enzalutamide Extends Survival in Men with Metastatic Prostate Cancer
Lenalidomide plus R-CHOP Improves Outcomes in Patients with Lymphoma
Medicaid Coverage for Hematopoietic Cell Transplantation Varies among States
Gemtuzumab Ozogamicin Improves Overall Survival in Patients with AML, Warrants New Considerations [ Read More ]

Predictive Testing Holds More Value to Oncology Stakeholders than Prognostic Testing

Wayne Kuznar

AVBCC 2014 4th Annual Conference

Los Angeles, CA—Predictive testing offers greater value over prognostic testing to most stakeholders in cancer care, because it has a direct impact on disease treatment rather than simply predicting the course of the disease (which is, ironically, the role of prognostic testing), said S. Macey Johnson III, MBA, Vice President, Managed Care and Reimbursement, bioTheranostics, San Diego, CA, at the Fourth Annual Conference of the Association for Value-Based Cancer Care. [ Read More ]

Payer Challenges in Oncology: Establishing Standards and Access to Quality Care

Wayne Kuznar

AVBCC 2014 4th Annual Conference

Los Angeles, CA—Payers are scrambling to devise effective strategies to cope with rapidly changing access to quality cancer care as a result of escalating costs. At the Fourth Annual Conference of the Association for Value-Based Cancer Care, John Fox, MD, MHA, Associate Vice President of Medical Affairs at Priority Health, Grand Rapids, MI, tackled changing access and payer challenges in oncology. [ Read More ]

Value Propositions – September 2014

Value Propositions

Study Identifies 2 Novel Mutations Responsible for Lung Cancer Resistance and How to Overcome It;
Kaiser Permanente Implements Value-Based Care/Payment Model;
UK National Health Services Increases Funds for Cancer Drugs Research;
NIH Launches Second Personalized Medicine Clinical Trial in Lung Cancer [ Read More ]